Literature DB >> 11751404

The FOXP1 winged helix transcription factor is a novel candidate tumor suppressor gene on chromosome 3p.

A H Banham1, N Beasley, E Campo, P L Fernandez, C Fidler, K Gatter, M Jones, D Y Mason, J E Prime, P Trougouboff, K Wood, J L Cordell.   

Abstract

The JC12 monoclonal antibody recognizes a previously unknown nuclear protein that showed a restricted distribution in normal tonsil and was also overexpressed in a subset of diffuse large B-cell lymphomas. Using this reagent, we expression cloned cDNAs encoding its antigenic target and identified this protein as a novel putative transcription factor, FOXP1. The FOXP1 protein sequence contains predicted domains characteristic of transcription factors, including a winged helix DNA-binding motif, a second potential DNA-binding motif, a C(2)H(2) zinc finger, nuclear localization signals, coiled-coil regions, PEST sequences, and potential transactivation domains. The FOXP1 gene has been mapped to chromosome 3p14.1, a region that commonly shows loss of heterozygosity in a wide range of tumors and which is reported to contain a tumor suppressor gene(s). Using tissue arrays and immunohistochemistry, we demonstrate that both the FOXP1 mRNA and protein are widely expressed in normal tissues. The levels of FOXP1 mRNA were compared in paired normal and tumor tissues (from the same patient) using a tissue array containing cDNAs extracted from 68 samples taken from kidney, breast, prostate, uterus, ovary, cervix, colon, lung, stomach, rectum, small intestine, and from nine cancer cell lines. Differences in FOXP1 mRNA expression between normal and tumor samples were observed in 51% of cases. Most striking was the comparative loss of expression in 73% of colon tumors and comparative overexpression of FOXP1 mRNA in 75% of stomach tumors. Analysis of the FOXP1 mRNA expression in normal tissues (not taken from cancer patients) indicated that loss of FOXP1 expression may occur in some histologically normal tissues adjacent to tumors. Immunohistochemical analysis of FOXP1 protein expression was performed on 128 solid tumors, including 16 renal, 9 breast, 12 lung, 20 colon, 21 stomach, 10 head and neck, 35 prostate, and 5 pancreatic cases. Complete loss of expression, increased expression, and cytoplasmic mislocalization of the predominantly nuclear FOXP1 protein were frequently observed in neoplastic cells. Our study identifies FOXP1 as a new candidate tumor suppressor gene localized to the chromosome 3p14.1 region.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11751404

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  87 in total

1.  Transcriptional and DNA binding activity of the Foxp1/2/4 family is modulated by heterotypic and homotypic protein interactions.

Authors:  Shanru Li; Joel Weidenfeld; Edward E Morrisey
Journal:  Mol Cell Biol       Date:  2004-01       Impact factor: 4.272

2.  Reciprocal expression of the endocytic protein HIP1R and its repressor FOXP1 predicts outcome in R-CHOP-treated diffuse large B-cell lymphoma patients.

Authors:  K K Wong; D M Gascoyne; P J Brown; E J Soilleux; C Snell; H Chen; L Lyne; C H Lawrie; R D Gascoyne; L M Pedersen; M B Møller; K Pulford; D Murphy; T M Green; A H Banham
Journal:  Leukemia       Date:  2013-07-25       Impact factor: 11.528

3.  The FOXP1 transcription factor is expressed in the majority of follicular lymphomas but is rarely expressed in classical and lymphocyte predominant Hodgkin's lymphoma.

Authors:  Philip Brown; Teresa Marafioti; Rajko Kusec; Alison H Banham
Journal:  J Mol Histol       Date:  2005-05       Impact factor: 2.611

4.  Foxp3 interacts with nuclear factor of activated T cells and NF-kappa B to repress cytokine gene expression and effector functions of T helper cells.

Authors:  Estelle Bettelli; Maryam Dastrange; Mohamed Oukka
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-24       Impact factor: 11.205

5.  miR-3687 Overexpression Promotes Bladder Cancer Cell Growth by Inhibiting the Negative Effect of FOXP1 on Cyclin E2 Transcription.

Authors:  Qipeng Xie; Caiyi Chen; Haiying Li; Jiheng Xu; Lei Wu; Yuan Yu; Shuwei Ren; Hongyan Li; Xiaohui Hua; Huiying Yan; Dapang Rao; Huxiang Zhang; Honglei Jin; Haishan Huang; Chuanshu Huang
Journal:  Mol Ther       Date:  2019-03-15       Impact factor: 11.454

6.  Molecular cloning, characterization, and developmental expression of foxp1 in zebrafish.

Authors:  Lu Cheng; Mei Chong; Weiwei Fan; Xiaofang Guo; Wenjuan Zhang; Xueyan Yang; Fan Liu; Yonghao Gui; Daru Lu
Journal:  Dev Genes Evol       Date:  2007-09-18       Impact factor: 0.900

7.  Prognostic markers and gene abnormalities in subgroups of diffuse large B-cell lymphoma: single center experience.

Authors:  Petra Korać; Mara Dominis
Journal:  Croat Med J       Date:  2008-10       Impact factor: 1.351

8.  Genetic and pathologic evolution of early secondary gliosarcoma.

Authors:  Kari-Elise T Codispoti; Stacy Mosier; Robert Ramsey; Ming-Tseh Lin; Fausto J Rodriguez
Journal:  Brain Tumor Pathol       Date:  2013-01-17       Impact factor: 3.298

9.  Downregulation of FOXP1 is required during germinal center B-cell function.

Authors:  Ainara Sagardoy; Jose I Martinez-Ferrandis; Sergio Roa; Karen L Bunting; María Angela Aznar; Olivier Elemento; Rita Shaknovich; Lorena Fontán; Vicente Fresquet; Ignacio Perez-Roger; Eloy F Robles; Linde De Smedt; Xavier Sagaert; Ari Melnick; Jose A Martinez-Climent
Journal:  Blood       Date:  2013-04-11       Impact factor: 22.113

10.  Disruption of neural progenitors along the ventricular and subventricular zones in periventricular heterotopia.

Authors:  Russell J Ferland; Luis Federico Batiz; Jason Neal; Gewei Lian; Elizabeth Bundock; Jie Lu; Yi-Chun Hsiao; Rachel Diamond; Davide Mei; Alison H Banham; Philip J Brown; Charles R Vanderburg; Jeffrey Joseph; Jonathan L Hecht; Rebecca Folkerth; Renzo Guerrini; Christopher A Walsh; Esteban M Rodriguez; Volney L Sheen
Journal:  Hum Mol Genet       Date:  2008-11-07       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.